NEW YORK, NY / ACCESS Newswire / March 18, 2025 / The Investor Summit is excited to announce that presentations from Q1 Investor Summit are now available for on-demand viewing. Attendees and investors...
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / The Investor Summit Group (ISG), today announced that Ori Warshavsky, Chief Operating Officer - US Operations and Jonny Missulawin, Chief Financial...
PolyPid collaborates with ImmunoGenesis to enhance solid tumor treatment using innovative drug delivery technologies.Quiver AI SummaryPolyPid Ltd. has announced a collaboration with ImmunoGenesis, Inc....
PolyPid Ltd. faces Nasdaq non-compliance but has potential funding options to regain stockholder equity requirements.Quiver AI SummaryPolyPid Ltd., a late-stage biopharma company focused on improving surgical...
Signed Exclusive Licensing Agreement for Commercialization of D-PLEX100 in Europe for Potentially Over $110 Million in Upfront and Milestone Payments, Plus...
PETACH TIKVA, Israel, July 27, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company...
Efficacy Data of D-PLEX100 in the Prevention of Post-Abdominal Surgery Incisional Infection in High-Risk Patients will be Presented During a Podium...
PETACH TIKVA, Israel, June 15, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming...
• Enrollment of 950 Patients, the Minimum Number of Patients Targeted for the SHIELD I Study, Expected Within Days • Top-line Results Expected by End of...
• Planned Unblinded Interim Analysis of Phase 3 SHIELD I Trial of D-PLEX100 in Abdominal Soft Tissue Surgery Expected to Occur Imminently • Recruitment...